Interpace Biosciences Inc IPO év
Mi az Interpace Biosciences Inc IPO év?
A IPO év az Interpace Biosciences Inc - 1998
Mi a IPO év meghatározása?
A kezdeti nyilvános ajánlattétel olyan nyilvános ajánlattétel, amelyben a társaság részvényeit általában olyan intézményi befektetőknek adják el, akik viszont értékpapírcserében először értékesítik a nagyközönségnek.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO év a Health Care szektor a NASDAQ-on cégekben a Interpace Biosciences Inc -hoz képest
Mit csinál Interpace Biosciences Inc?
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
ipo év -hoz hasonló cégek Interpace Biosciences Inc
- Rimfire Pacific Mining NL nak IPO év 1997 van
- Flagstar nak IPO év 1997 van
- Active PLC nak IPO év 1997 van
- Redflex nak IPO év 1997 van
- Norwest NL nak IPO év 1997 van
- Kaleyra Inc nak IPO év 1997 van
- Interpace Biosciences Inc nak IPO év 1998 van
- Tuesday Morning nak IPO év 1999 van
- American Axle & Manufacturing Inc nak IPO év 1999 van
- Liontrust Asset Management Plc nak IPO év 1999 van
- Empire Petroleum nak IPO év 1999 van
- Surefire Resources NL nak IPO év 1999 van
- NXT Solutions nak IPO év 1999 van